Geron (GERN) Financials: History & Chart

Geron Corporation(GERN)

Biotechnology · Foster City, CA

$1.23+0.02 (+1.65%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

About Geron Corporation

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Foster City, CA

258 employees

www.geron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Harout Semerjian

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	204.56M	57.48M	51.84M	48.02M	47.23M	49.04M	39.60M	47.54M	28.27M
Cost of Goods Sold	34.35M	9.24M	1.69M	1.31M	22.11M	1.19M	1.21M	783K	456K
Gross Profit	170.21M	48.24M	50.15M	46.71M	25.11M	47.85M	38.40M	46.75M	27.82M
Gross Profit Margin	83.2%	83.9%	96.7%	97.3%	53.2%	97.6%	97.0%	98.4%	98.4%
Total Operating Expenses	207.62M	60.74M	50.38M	57.50M	39.00M	60.30M	55.10M	66.80M	56.03M
Research & Development	73.89M	22.03M	14.96M	15.83M	21.07M	21.74M	15.08M	23.43M	20.15M
Selling, General & Administrative	154.96M	38.86M	35.42M	41.67M	39.00M	38.56M	40.02M	43.37M	35.88M
Operating Income (EBIT)	-37.41M	-12.50M	-236K	-10.79M	-13.89M	-12.45M	-16.70M	-20.05M	-28.21M
Operating Margin	-18.3%	-21.7%	-0.5%	-22.5%	-29.4%	-25.4%	-42.2%	-42.2%	-99.8%
Income Before Tax (EBT)	-69.89M	-16.68M	-3.64M	-31.14M	-18.43M	-16.38M	-19.84M	-25.35M	-26.45M
Interest Income	14.70M	2.97M	3.42M	4.04M	4.26M	4.66M	5.15M	5.16M	4.88M
Interest Expense	30.23M	7.15M	7.15M	7.30M	8.64M	8.52M	8.20M	8.71M	3.05M
Other Income/Expense	-32.48M	-4.18M	-3.41M	-20.35M	-4.54M	-3.92M	-3.13M	-5.30M	1.77M
Net Income	-69.89M	-16.68M	-3.64M	-31.14M	-18.43M	-16.38M	-19.84M	-25.35M	-26.45M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-34.2%	-29.0%	-7.0%	-64.9%	-39.0%	-33.4%	-50.1%	-53.3%	-93.5%
EBITDA	-36.54M	-12.36M	90K	-10.52M	-13.76M	-12.14M	-16.40M	-19.73M	-28.01M
EBITDA Margin	-17.9%	-21.5%	0.2%	-21.9%	-29.1%	-24.8%	-41.4%	-41.5%	-99.1%
Depreciation & Amortization	865K	136K	326K	275K	128K	309K	308K	316K	201K
EPS Basic	-0.10	-0.02	-0.01	-0.05	-0.03	-0.02	-0.03	-0.04	-0.04
EPS Diluted	-0.10	-0.02	-0.01	-0.05	-0.03	-0.02	-0.03	-0.04	-0.04
Weighted Average Basic Shares	670.70M	670.70M	669.38M	667.16M	667.10M	666.17M	665.90M	646.03M	662.16M
Weighted Average Diluted Shares	670.70M	670.70M	669.38M	667.16M	667.10M	666.17M	665.90M	646.03M	662.16M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	183.88M	76.99M	237K	596K	1.39M	253K	460K	1.07M
Cost of Goods Sold	4.75M	1.26M	0.00	0.00	0.00	50.05M	51.27M	12.72M
Gross Profit	179.14M	75.74M	237K	596K	1.39M	-49.80M	-50.81M	-11.66M
Gross Profit Margin	97.4%	98.4%	100.0%	100.0%	100.0%	-19683.4%	-11046.1%	-1093.5%
Total Operating Expenses	232.97M	249.47M	194.18M	139.15M	115.39M	27.11M	21.69M	32.14M
Research & Development	73.72M	103.74M	125.05M	95.52M	85.73M	51.49M	52.07M	13.43M
Selling, General & Administrative	159.26M	145.73M	69.14M	43.63M	29.66M	27.11M	21.69M	18.71M
Operating Income (EBIT)	-53.84M	-173.73M	-193.94M	-138.55M	-114.00M	-76.91M	-72.50M	-31.07M
Operating Margin	-29.3%	-225.6%	-81832.9%	-23246.6%	-8183.7%	-30400.4%	-15762.0%	-2914.9%
Income Before Tax (EBT)	-85.78M	-174.57M	-184.13M	-141.90M	-116.11M	-75.62M	-68.55M	-27.02M
Interest Income	18.12M	19.61M	18.15M	2.53M	527K	1.83M	4.22M	3.25M
Interest Expense	32.66M	18.50M	8.31M	6.88M	3.74M	760K	N/A	N/A
Other Income/Expense	-31.95M	-840K	9.82M	-3.35M	-2.11M	1.30M	3.96M	4.06M
Net Income	-85.78M	-174.57M	-184.13M	-141.90M	-116.11M	-75.62M	-68.55M	-27.02M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-46.7%	-226.7%	-77690.7%	-23808.9%	-8335.4%	-29888.1%	-14901.7%	-2534.4%
EBITDA	-52.63M	-172.51M	-192.91M	-137.68M	-113.22M	-76.75M	-72.44M	-31.01M
EBITDA Margin	-28.6%	-224.1%	-81397.0%	-23101.0%	-8127.5%	-30337.9%	-15748.0%	-2909.4%
Depreciation & Amortization	1.20M	1.22M	1.03M	868K	783K	158K	64K	59K
EPS Basic	-0.13	-0.27	-0.32	-0.37	-0.37	-0.28	-0.33	-0.15
EPS Diluted	-0.13	-0.27	-0.32	-0.37	-0.37	-0.28	-0.33	-0.15
Weighted Average Basic Shares	666.66M	646.03M	570.65M	380.78M	327.63M	271.46M	190.16M	176.50M
Weighted Average Diluted Shares	666.66M	646.03M	570.65M	380.78M	327.63M	271.46M	190.16M	176.50M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.